Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9685966 | 0.73 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL11301702 | 0.73 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL7057172 | 0.68 | ALDH1A1 (0.33) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL8108558 | 0.68 | HSP90AA1 (0.35) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL4428227 | 0.68 | ALDH1A1 (0.33) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL22471432 | 0.68 | PGR (0.36) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL17356348 | 0.68 | LMNA (0.36) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL22846898 | 0.67 | ALDH1A1 (0.32) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL22847505 | 0.66 | ADRA1D (0.37) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| SCHEMBL9812789 | 0.64 | ALDH1A1 (0.37) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | claimed |
| WO-2009042064-A2 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-02 | — | — | WO | claimed |
| US-9365604-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140371168-A1 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-12-18 | — | — | US | disclosed |
| US-8741858-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS | 2014-06-03 | — | — | US | disclosed |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009042064-A2 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371168-A1 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | ENTPD5, SLC29A2, SLC29A1 | ALDH1A1 4129/4885LMNA 4542/4885MAPT 542/4885 |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | ENTPD5, SLC29A2, SLC29A1 | ALDH1A1 4203/4885LMNA 4539/4885MAPT 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.